Cell/Gene Tx channel feed

What can a 157-year-old phar­ma gi­ant bring to the ta­ble of cell and gene ther­a­pies? Quite a bit, Bay­er says

5 years ago
Pharma

Take­da eyes path­way to nat­ur­al killer ther­a­pies, tee­ing up $100M to part­ner with KSQ for its CRISPR-screened mol­e­cules

5 years ago
Deals

Spark co-founder Kathy High joins a long­time col­lab­o­ra­tor at AskBio, help­ing steer Bay­er's gene ther­a­py push

5 years ago
People

Still reel­ing from re­jec­tion, Bio­Marin re­ports a glimpse of those 2-year val­rox da­ta FDA was look­ing for — but is it enough to change reg­u­la­tors' minds?

5 years ago
R&D

Blue­bird spins it­self in­to two com­pa­nies, sev­er­ing gene ther­a­py and can­cer units

5 years ago

Nas­daq rings in its first biotech IPOs of 2021: a CAR-T spe­cial­ist from Chi­na, a can­cer port­fo­lio play, and a SPAC

5 years ago
Financing
China

FDA of­fers first thoughts on neu­rode­gen­er­a­tive dis­ease gene ther­a­pies

5 years ago
FDA+

Mana joins the hec­tic fight against sol­id tu­mors with an ‘off-the-shelf’ can­di­date an­gling for an IND this year

5 years ago
Financing

Rid­ing on rosy es­ti­mates of Zol­gens­ma sales, Re­genxBio sells part of its roy­al­ty for $200M

5 years ago
Deals

FDA slaps a hold on Voy­ager's lead gene ther­a­py over 'M­RI ab­nor­mal­i­ties'

5 years ago
FDA+

Patrick Soon-Sh­iong merges trou­bled 'moon shot' Nan­tK­west and cell ther­a­py play Im­mu­ni­ty­Bio in late-stage ex­pan­sion

5 years ago
Deals

Af­ter leav­ing Wall Street to launch a gene ther­a­py up­start, Rachel McMinn nabs $115M to dri­ve her first can­di­date to the clin­ic

5 years ago
Financing

Af­ter reel­ing back a gene ther­a­py from Sanofi, a North Car­oli­na up­start bags enough mon­ey to do some­thing about it

5 years ago
Financing

Eli Lil­ly picks up gene ther­a­py play­er Pre­vail in deal worth $1B+, mak­ing good on bolt-on pledge from ear­li­er this year

5 years ago
Deals

No­vo Hold­ings in­vests in Hemab, a com­pa­ny go­ing against the he­mo­phil­ia gene ther­a­py grain with a plan for bis­pecifics

5 years ago
Deals

Bay­er picks up off-the-shelf CAR-T ap­proach from Atara, spot­light­ing a Memo­r­i­al Sloan Ket­ter­ing break­through

5 years ago
Deals

#ASH20: As Bris­tol My­ers awaits FDA word, the CAR-T BC­MA lead­ers go head-to-head once again. This time, they're not alone

5 years ago
R&D

#ASH20 Al­lo­gene's David Chang makes the case for an off-the-shelf CAR-T in the jam packed an­ti-BC­MA field

5 years ago
R&D

#ASH20: David Alt­shuler and the Ver­tex/CRISPR team hit a his­toric mile­stone in the hunt for a cu­ra­tive gene edit­ing ap­proach to sick­le cell dis­ease, be­ta tha­lassemia

5 years ago

Penn re­searchers find a way through the labyrinth keep­ing CAR-T from sol­id tu­mors

5 years ago
Discovery

Bay­er con­tin­ues its cell and gene ther­a­py push, en­velop­ing dif­fer­ent projects un­der one strate­gic roof while hunt­ing new deals

5 years ago
Pharma

Scoop: Google’s GV spear­heads the Spot­light syn­di­cate — back­ing an up­start biotech aimed at ‘de­moc­ra­tiz­ing’ gene edit­ing

5 years ago
Financing

Cata­ma­ran Bio sails in­to the CAR-NK wa­ters with a $42M launch round

5 years ago
Financing

George Church backs a start­up so­lu­tion to the mas­sive gene ther­a­py man­u­fac­tur­ing bot­tle­neck

5 years ago
Startups
First page Previous page 41424344454647 Next page Last page
A service from the Financial Times